Merck Sharp & Dohme LLC (MSD) has reported new plasma kallikrein (KLKB1) inhibitors potentially useful for the treatment of diabetic macular edema, cancer, hereditary angioedema, uveitis, pancreatitis, arthritis, nephropathy and inflammatory disorders and among others.